Resources from the same session
1203O - FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
Presenter: Sylvie Lorenzen
Session: Proffered Paper session 2: GI, upper digestive
Resources:
Abstract
Slides
Webcast
LBA60 - Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study
Presenter: Christelle de la Fouchardiere
Session: Proffered Paper session 2: GI, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LAB60
Presenter: Hanneke Wilmink
Session: Proffered Paper session 2: GI, upper digestive
Resources:
Slides
Webcast
LBA12 - Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Presenter: Antoine Hollebecque
Session: Proffered Paper session 2: GI, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA12
Presenter: Chiara Braconi
Session: Proffered Paper session 2: GI, upper digestive
Resources:
Slides
Webcast